Patient characteristics and vitamin D insufficiency discovery cohort
| . | Vitamin D sufficient (n = 271) . | Vitamin D insufficient (n = 119) . | P . |
|---|---|---|---|
| Median age at diagnosis, y | 62 | 64 | .38 |
| Male | 178 (65.7%) | 89 (74.8%) | .07 |
| Rai stage at diagnosis | |||
| 0 | 131 (48.3%) | 49 (41.5%) | trend P = .23 |
| I | 111 (41.0%) | 58 (49.2%) | |
| II | 25 (9.2%) | 4 (3.4%) | |
| III | 1 (0.4%) | 5 (4.2%) | |
| IV | 3 (1.1%) | 2 (1.7%) | |
| Season at CLL diagnosis | |||
| Spring | 60 (22.1%) | 31 (26.1%) | .75 |
| Summer | 84 (31.0%) | 34 (28.6%) | |
| Fall | 66 (24.4%) | 25 (21.0%) | |
| Winter | 61 (22.5%) | 29 (24.4%) | |
| CD38 | |||
| Negative | 171 (74.0%) | 63 (66.3%) | .16 |
| Positive | 60 (26.0%) | 32 (33.7%) | |
| ZAP-70 | |||
| Negative | 153 (69.9%) | 62 (67.4%) | .67 |
| Positive | 66 (30.1%) | 30 (32.6%) | |
| IGHV | |||
| Mutated | 129 (63.9%) | 47 (56.6%) | .25 |
| Unmutated | 73 (36.1%) | 36 (43.4%) | |
| CD49d | |||
| Negative | 96 (68.1%) | 38 (65.5%) | .73 |
| Positive | 45 (31.9%) | 20 (34.5%) | |
| FISH (prior to treatment) | |||
| 13q− | 96 (43.8%) | 30 (33.0%) | .10 |
| Normal | 53 (24.2%) | 30 (33%) | |
| +12 | 41 (18.7%) | 16 (17.6%) | |
| 11q− | 19 (8.7%) | 7 (7.7%) | |
| 17p− | 5 (2.3%) | 7 (7.7%) | |
| Other | 5 (2.3%) | 1 (1.1%) |
| . | Vitamin D sufficient (n = 271) . | Vitamin D insufficient (n = 119) . | P . |
|---|---|---|---|
| Median age at diagnosis, y | 62 | 64 | .38 |
| Male | 178 (65.7%) | 89 (74.8%) | .07 |
| Rai stage at diagnosis | |||
| 0 | 131 (48.3%) | 49 (41.5%) | trend P = .23 |
| I | 111 (41.0%) | 58 (49.2%) | |
| II | 25 (9.2%) | 4 (3.4%) | |
| III | 1 (0.4%) | 5 (4.2%) | |
| IV | 3 (1.1%) | 2 (1.7%) | |
| Season at CLL diagnosis | |||
| Spring | 60 (22.1%) | 31 (26.1%) | .75 |
| Summer | 84 (31.0%) | 34 (28.6%) | |
| Fall | 66 (24.4%) | 25 (21.0%) | |
| Winter | 61 (22.5%) | 29 (24.4%) | |
| CD38 | |||
| Negative | 171 (74.0%) | 63 (66.3%) | .16 |
| Positive | 60 (26.0%) | 32 (33.7%) | |
| ZAP-70 | |||
| Negative | 153 (69.9%) | 62 (67.4%) | .67 |
| Positive | 66 (30.1%) | 30 (32.6%) | |
| IGHV | |||
| Mutated | 129 (63.9%) | 47 (56.6%) | .25 |
| Unmutated | 73 (36.1%) | 36 (43.4%) | |
| CD49d | |||
| Negative | 96 (68.1%) | 38 (65.5%) | .73 |
| Positive | 45 (31.9%) | 20 (34.5%) | |
| FISH (prior to treatment) | |||
| 13q− | 96 (43.8%) | 30 (33.0%) | .10 |
| Normal | 53 (24.2%) | 30 (33%) | |
| +12 | 41 (18.7%) | 16 (17.6%) | |
| 11q− | 19 (8.7%) | 7 (7.7%) | |
| 17p− | 5 (2.3%) | 7 (7.7%) | |
| Other | 5 (2.3%) | 1 (1.1%) |